Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Torrent Pharmaceuticals reported strong performance in its branded markets, which contributed 76% of total revenue in Q3 FY25.
- India business demonstrated robust growth at 12% for the quarter and 13% YTD December.
- Brazil experienced 10% constant currency growth for the quarter and 12% YTD December, despite a 17% currency depreciation impact.
- Germany achieved 4% growth in Q3 and 7% YTD December, driven by consistent wins in incremental tenders.
- Insulin revenue was nil during the quarter due to a temporary halt in manufacturing, but dispatches have resumed in January 2025, with spillover revenue expected in Q4.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.